These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11448050)

  • 21. Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women.
    Karara AH; Harrison LI; Melikian AP; Poola N; Morrison D; Bourg D; Bourg L; Zurth C
    J Clin Pharmacol; 2014 May; 54(5):520-7. PubMed ID: 24474034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of an intravaginal ring for the controlled delivery of 17 beta-estradiol as its 3-acetate ester.
    Woolfson AD; Elliott GR; Gilligan CA; Passmore CM
    J Control Release; 1999 Sep; 61(3):319-28. PubMed ID: 10477804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro release profile of estradiol transdermal therapeutic systems.
    Tymes NW; Shah VP; Skelly JP
    J Pharm Sci; 1990 Jul; 79(7):601-2. PubMed ID: 2398467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transdermal delivery of nicardipine: an approach to in vitro permeation enhancement.
    Aboofazeli R; Zia H; Needham TE
    Drug Deliv; 2002; 9(4):239-47. PubMed ID: 12511202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-performance liquid chromatographic determination of 17beta-estradiol and 17beta-estradiol-3-acetate solubilities and diffusion coefficents in silicone elastromeric intravaginal rings.
    Russell JA; Malcolm RK; Campbell K; Woolfson AD
    J Chromatogr B Biomed Sci Appl; 2000 Jul; 744(1):157-63. PubMed ID: 10985577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel pulsatile drug delivery system based on the physiochemical reaction between acrylic copolymer and organic acid: in vitro and in vivo evaluation.
    Zhang Z; Qi X; Li X; Xing J; Zhu X; Wu Z
    Int J Pharm; 2014 Feb; 462(1-2):66-73. PubMed ID: 24368107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation design and in vitro ex vivo evaluation of transdermal patches of Cinnarizine.
    Yamsani VV; Mudulaghar MK; Afreen S; Wajid S; Ravula SK; Babelghaith SD
    Pak J Pharm Sci; 2017 Nov; 30(6):2075-2083. PubMed ID: 29175776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PREPARATION, IN VITRO AND IN VIVO CHARACTERIZATION OF HYDROPHOBIC PATCHES OF A HIGHLY WATER SOLUBLE DRUG FOR PROLONGED PLASMA HALF LIFE: EFFECT OF PERMEATION ENHANCERS.
    Yaqoob A; Ahmad M; Mahmood A; Sarfraz RM
    Acta Pol Pharm; 2016 Nov; 73(6):1639-1648. PubMed ID: 29634120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acrylic matrix type nicotine transdermal patches: in vitro evaluations and batch-to-batch uniformity.
    Pongjanyakul T; Prakongpan S; Priprem A
    Drug Dev Ind Pharm; 2003 Sep; 29(8):843-53. PubMed ID: 14570305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Release performance of a poorly soluble drug from a novel, Eudragit-based multi-unit erosion matrix.
    Mehta KA; Kislalioglu MS; Phuapradit W; Malick AW; Shah NH
    Int J Pharm; 2001 Feb; 213(1-2):7-12. PubMed ID: 11165089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Miscibility and interactions between 17beta-estradiol and Eudragit RS in solid dispersion.
    Wiranidchapong C; Tucker IG; Rades T; Kulvanich P
    J Pharm Sci; 2008 Nov; 97(11):4879-88. PubMed ID: 18351595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted brain delivery of 17 beta-estradiol via nasally administered water soluble prodrugs.
    Al-Ghananeem AM; Traboulsi AA; Dittert LW; Hussain AA
    AAPS PharmSciTech; 2002; 3(1):E5. PubMed ID: 12919005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization.
    Ah YC; Choi JK; Choi YK; Ki HM; Bae JH
    Int J Pharm; 2010 Jan; 385(1-2):12-9. PubMed ID: 19833177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transdermal delivery of alprazolam from a monolithic patch: formulation based on in vitro characterization.
    Soler LI; Boix A; Lauroba J; Colom H; Domenech J
    Drug Dev Ind Pharm; 2012 Oct; 38(10):1171-8. PubMed ID: 22204649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ocular inserts for controlled delivery of pefloxacin mesylate: preparation and evaluation.
    Sultana Y; Aqil M; Ali A
    Acta Pharm; 2005 Sep; 55(3):305-14. PubMed ID: 16375841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of a 7-day 17 beta-estradiol transdermal delivery system: effect of application site and repeated applications on serum concentrations of estradiol and estrone.
    Boyd RA; Yang BB; Abel RB; Eldon MA; Sedman AJ; Forgue ST
    J Clin Pharmacol; 1996 Nov; 36(11):998-1005. PubMed ID: 8973988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formulation considerations in the design of topical, polymeric film-forming systems for sustained drug delivery to the skin.
    Frederiksen K; Guy RH; Petersson K
    Eur J Pharm Biopharm; 2015 Apr; 91():9-15. PubMed ID: 25595740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
    Rohr UD; Nauert C; Stehle B
    Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transdermal application of steroid hormones for contraception.
    Sitruk-Ware R
    J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):247-51. PubMed ID: 7626463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of bioequivalence of two 7-day 17beta-estradiol transdermal delivery systems by anatomical site.
    Harrison LL; Harari D
    J Clin Pharmacol; 2002 Oct; 42(10):1134-41. PubMed ID: 12362928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.